Let’s Jump into the TCR2 Therapeutics Inc. (NASDAQ:TCRR) Stock Forecast

In the latest trading session, 1,995,694 TCR2 Therapeutics Inc.(NASDAQ:TCRR) shares changed hands as the company’s beta touched 0. With the company’s most recent per share price at $29.44 changing hands around $0.2 or 0.01% at last look, the market valuation stands at $983.95 Million. TCRR’s current price is a discount, trading about -21.81% off its 52-week high of $35.86. The share price had its 52-week low at $5.84, which suggests the current value is an impressive 80.16% up since then. When we look at TCR2 Therapeutics Inc.’s average trading volume, we note the 10-day average is 1.2 Million shares, with the 3-month average coming to 399.2 Million.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Analysts give the TCR2 Therapeutics Inc. (TCRR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.7. If we narrow down to specifics, the data shows that none out of 9 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended TCRR as a Hold, 9 felt it is a Buy and none rated the stock as Underweight. TCR2 Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.56.

TCR2 Therapeutics Inc. (NASDAQ:TCRR) trade information

Instantly TCRR is in green as seen in intraday trades today with action 0.68%, the performance over the past five days has been red. The jump to weekly highs of $35.86- on Monday, Dec 14 added 17.9% to the stock’s daily price. The company’s shares are showing year-to-date upside of 1.06%, with the 5-day performance at -0.1% in the red. However, in the 30-day time frame, TCR2 Therapeutics Inc. (NASDAQ:TCRR) is 0.06% up. Looking at the short shares, we see there were 2.32 Million shares sold at short interest cover period of 0.01 days.

The consensus price target for the stock as assigned by Wall Street analysts is $46.89, meaning bulls need an upside of 59.27% from its current market value. According to analyst projections, TCRR’s forecast low is $37 with $65 as the target high. To hit the forecast high, the stock’s price needs a +120.79% upsurge from its current level, while the stock would need to tank 25.68% for it to hit the projected low.

TCR2 Therapeutics Inc. (TCRR) estimates and forecasts

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0%. The 2020 estimates are for TCR2 Therapeutics Inc. earnings to decrease by -79.7%, but the outlook for the next 5-year period is at 0% per year.

TCR2 Therapeutics Inc. (NASDAQ:TCRR)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.55% of TCR2 Therapeutics Inc. shares while 96.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 98.19%. There are 130 institutions holding the TCR2 Therapeutics Inc. stock share, with MPM Asset Management, LLC the top institutional holder. As of Sep 29, 2020, the company held 12.12% of the shares, roughly 4.05 Million TCRR shares worth $82.31 Million.

MPM ONCOLOGY IMPACT MANAGEMENT LP holds the second largest percentage of outstanding shares, with 10.09% or 3.37 Million shares worth $68.5 Million as of Sep 29, 2020.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Among Mutual Funds, the top two as of Sep 29, 2020 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 627142 shares estimated at $12.74 Million under it, the former controlled 1.88% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.69% of the shares, roughly 563.8 Thousand shares worth around $15.36 Million.

This Secret NYSE Telecom Trading at $1.36 gets $35.00 Price Target by 2 Analyst!

There is a secret stock that is LOADED with opportunity for savvy investors to make a fortune!

Get all the details here >>


Latest posts